A study published online last week in the journal Neurology® reports encouraging results for a new medication designed to prevent chronic migraine. Teva Pharmaceuticals reports that its drug TEV-48125 was associated with fewer headache hours within 3 to 7 days in a study of patients with a history of chronic migraine. TEV-48125 is an antibody that blocks the calcitonin gene-related peptide that plays a role in migraine pain. Study author Marcelo Bigal, MD, PhD, of Teva commented on the significance of the phase 2b study outcome: “Most people who receive preventive medication for chronic migraine stop using them, and one reason for that is the drugs can take a long time to become effective. If these results can be confirmed with larger studies, this could be exciting for people with migraine.”
The study encompassed 261 people with a history of chronic migraine, averaging 162 headache hours per month, 22 days with headache per month, for an average duration of 18 years. 87 subjects received a low dose injection of TEV-48125 monthly for 3 months, 85 subjects received a high dose, and 89 received placebo. Using patient reports of headache hours, the study found fewer headache hours within 3 days for the high-dose cohort compared to placebo, and within 7 days for the low-dose group. Read a news story about the study findings here. The journal abstract may be accessed here.
Posted on June 15, 2016